The results indicated that the alum adjuvant and the built-in TLR7 agonist synergistically enhanced the anti-MUC1 antibody response, induced a Th1-biased immune response, and also boosted the MUC1 glycopeptide-specific memory CD8+ T cell immune response, significantly inhibiting tumor growth and prolonging mouse survival (144). Here, CD8A is linked to neoplasm.